← All indications
Problem Behavior
Troublesome or disruptive behavioral displays.
Drugs by status
Phase 4 trials (6)
Phase 2 trials (1)
Phase 1 trials (2)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (21)
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- National Institutes of Health (NIH)
- Douglas Sears
- National Jewish Health
- AGUNCO Obstetrics and Gynecology Centre
- Johns Hopkins University
- Universidad Nacional de Rosario
- Laval University
- State University of New York
- University of Colorado, Denver
- University of Vienna
- Sears, Douglas, M.D.
- Universidad Autonoma de Barcelona
- Hospital de Sant Pau i Santa Tecla de Tarragona
- Centro Clinico Colle Cesarano Tivoli Rome Italy
- State University of New York, Buffalo
- Johnson and Johnson
- Galatea Clinic
- Vall d'Hebron Institute of Research, Galatea Clinic
Organization Involved with Phase 3 Indications (16)
- Bristol-Myers Squibb
- Solvay
- Otsuka
- National Institute of Mental Health (NIMH)
- National Institute on Drug Abuse (NIDA)
- University of Pennsylvania
- Cancer Research Network
- University of Rochester
- Columbia University
- Joint Child Health Project, Mauritius
- University of California, San Diego
- City University of Hong Kong
- City University of New York
- The University of Hong Kong
- Janssen Pharmaceutica NV
- Wholistic Research and Education Foundation
Organization Involved with Phase 2 Indications (12)
- Forest Laboratories
- National Institute on Aging (NIA)
- Chiba University
- Radboud University
- University of Nebraska
- University of British Columbia
- University of Freiburg
- Hebrew University
- Department of Veteran Affairs
- European Union
- Obsessive Compulsive Foundation
- International Obsessive-Compulsive Disorder Foundation
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (8)